CenterBook Partners LP Sells 218,002 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

CenterBook Partners LP trimmed its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 31.6% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 472,075 shares of the company's stock after selling 218,002 shares during the quarter. CenterBook Partners LP owned about 0.30% of Xeris Biopharma worth $2,592,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of XERS. Federated Hermes Inc. increased its holdings in Xeris Biopharma by 36,542.7% in the 1st quarter. Federated Hermes Inc. now owns 687,783 shares of the company's stock worth $3,776,000 after purchasing an additional 685,906 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Xeris Biopharma by 166.2% in the fourth quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company's stock valued at $3,537,000 after buying an additional 651,481 shares during the period. Deutsche Bank AG increased its stake in shares of Xeris Biopharma by 492.8% in the first quarter. Deutsche Bank AG now owns 756,407 shares of the company's stock valued at $4,153,000 after buying an additional 628,807 shares during the period. Driehaus Capital Management LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at about $2,014,000. Finally, Millennium Management LLC increased its stake in shares of Xeris Biopharma by 34.8% in the fourth quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock valued at $6,606,000 after buying an additional 502,853 shares during the period. 42.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

XERS has been the subject of several recent research reports. Wall Street Zen cut Xeris Biopharma from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Oppenheimer increased their price target on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Xeris Biopharma presently has a consensus rating of "Moderate Buy" and an average target price of $6.25.

Xeris Biopharma Trading Up 0.7%

NASDAQ XERS traded up $0.04 during trading hours on Friday, hitting $5.27. 590,891 shares of the company's stock were exchanged, compared to its average volume of 2,063,991. The stock has a 50-day simple moving average of $4.79 and a 200 day simple moving average of $4.35. Xeris Biopharma Holdings, Inc. has a 1-year low of $2.10 and a 1-year high of $6.07. The firm has a market cap of $823.34 million, a price-to-earnings ratio of -17.55 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to the consensus estimate of $57.61 million. On average, sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Transactions at Xeris Biopharma

In other news, insider Kevin Mcculloch purchased 25,000 shares of the business's stock in a transaction on Friday, June 13th. The shares were acquired at an average price of $4.38 per share, for a total transaction of $109,500.00. Following the completion of the acquisition, the insider owned 1,708,585 shares in the company, valued at approximately $7,483,602.30. The trade was a 1.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 6.47% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.